Recombinant SARS-CoV-2 B.1.617.1 Spike GCN4-IZ Protein, CF
Recombinant SARS-CoV-2 B.1.617.1 Spike GCN4-IZ Protein, CF Summary
Product Specifications
| Recombinant SARS-CoV-2 Spike (Val16-Lys1211)(Gly142Asp, Glu154Lys, Leu452Arg, Glu484Gln, Asp614Gly, Pro681Arg, Gln1071His)(Arg682Ser, Arg685Ser, Lys986Pro, Val987Pro) Accession # YP_009724390.1 | GCN4-IZ | 6-His tag |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
10861-CV
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
10861-CV
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
| Reconstitution | Reconstitute at 500 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant SARS-CoV-2 B.1.617.1 Spike (GCN4-IZ) His-tag (Catalog # 10861-CV) binds Recombinant Human ACE-2 His-tag (933-ZN) in a functional ELISA.
View Larger
2 μg/lane of Recombinant SARS-CoV-2 B.1.617.1 Spike (GCN4-IZ) His-tag Protein (Catalog # 10861-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 139-167 kDa.
View Larger
Recombinant SARS-CoV-2 B.1.617.1 Kappa variant Spike protein His-tag (Catalog #10861-CV) was immobilized on a Biacore Sensor Chip CM5, and binding to recombinant human ACE-2 (933-ZN) was measured at a concentration range between 0.046 nM and 47.2 nM. The double-referenced sensorgram was fit to a 1:1 binding model to determine the binding kinetics and affinity, with an affinity constant of KD=1.819 nM.
Background: Spike
SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). A metallopeptidase, angiotensin-converting enzyme 2 (ACE-2), has been identified as a functional receptor for SARS-CoV-2 through interaction with a receptor binding domain (RBD) located at the C-terminus of S1 subunit (6, 7). The S protein of SARS-CoV-2 shares 75% and 29% amino acid sequence identity with S protein of SARS‑CoV-1 and MERS, respectively. A SARS-CoV-2 variant (B.1.617) carrying the amino acid substitution L452R and E484Q in the RBD was identified as a prevalent strain in India (8, 9). Whether these mutations in RBD would cause more severe symptom or decrease the efficacy of vaccine-induced immunity is still under investigation.
- Wu, F. et al. (2020) Nature 579:265.
- Tortorici, M.A. and D. Veesler (2019) Adv. Virus Res. 105:93.
- Bosch, B.J. et al. (2003). J. Virol. 77:8801.
- Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871.
- Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120.
- Li, W. et al. (2003) Nature 426:450.
- Wong, S.K. et al. (2004) J. Biol. Chem. 279:3197.
- Yadav, P.D. et al. (2021) bioRxiv https://doi.org/10.1101/2021.04.23.441101.
- Cherian, S. et al. (2021) bioRxiv https://doi.org/10.1101/2021.04.22.440932.
Citation for Recombinant SARS-CoV-2 B.1.617.1 Spike GCN4-IZ Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Novel Therapeutic Target Critical for SARS-CoV-2 Infectivity and Induction of the Cytokine Release Syndrome
Authors: Harless, WW;Lewis, B;Qorri, B;Abdulkhalek, S;Szewczuk, MR;
Cells
Species: N/A
Sample Types: DNA/Recombinant Protein
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant SARS-CoV-2 B.1.617.1 Spike GCN4-IZ Protein, CF
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant SARS-CoV-2 B.1.617.1 Spike GCN4-IZ Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
